Data Insights

ALTO-100 by Alto Neuroscience for Post-Traumatic Stress Disorder (PTSD): Likelihood of Approval

ALTO-100 is under clinical development by Alto Neuroscience and currently in Phase II for Post-Traumatic Stress Disorder (PTSD). According to...

Likelihood of Approval and Phase Transition Success Rate Model - ALTO-100 in Post-Traumatic Stress Disorder (PTSD)

Data Insights

200'S Series Novel Combinations (Dopamine Pathway) by Alto Neuroscience for Neurodegenerative Diseases: Likelihood of Approval

200'S Series Novel Combinations (Dopamine Pathway) is under clinical development by Alto Neuroscience and currently in Phase I for Neurodegenerative...

Likelihood of Approval and Phase Transition Success Rate Model - 200's Series Novel Combinations (Dopamine Pathway) in Neurodegenerative Diseases

Data Insights

200'S Series Novel Combinations (Dopamine Pathway) by Alto Neuroscience for Unspecified Psychiatric Disorders: Likelihood of Approval

200'S Series Novel Combinations (Dopamine Pathway) is under clinical development by Alto Neuroscience and currently in Phase I for Unspecified...

Data Insights

ALTO-203 by Alto Neuroscience for Major Depressive Disorder: Likelihood of Approval

ALTO-203 is under clinical development by Alto Neuroscience and currently in Phase II for Major Depressive Disorder. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - ALTO-203 in Major Depressive Disorder

Data Insights

Agomelatine by Alto Neuroscience for Major Depressive Disorder: Likelihood of Approval

Agomelatine is under clinical development by Alto Neuroscience and currently in Phase II for Major Depressive Disorder. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Agomelatine in Major Depressive Disorder

Data Insights

ALTO-202 by Alto Neuroscience for Major Depressive Disorder: Likelihood of Approval

ALTO-202 is under clinical development by Alto Neuroscience and currently in Phase II for Major Depressive Disorder. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - ALTO-202 in Major Depressive Disorder

Data Insights

ALTO-101 by Alto Neuroscience for Cognitive Impairment Associated With Schizophrenia (CIAS): Likelihood of Approval

ALTO-101 is under clinical development by Alto Neuroscience and currently in Phase II for Cognitive Impairment Associated With Schizophrenia (CIAS)....

Likelihood of Approval and Phase Transition Success Rate Model - ALTO-101 in Cognitive Impairment Associated With Schizophrenia (CIAS)